Lupus drug anifrolumab put to the test in everyday patients

NCT ID NCT07215754

Recruiting now Disease control Sponsor: University of Pisa Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study follows 300 people with active systemic lupus erythematosus (SLE) who are taking anifrolumab, a drug that blocks a key immune signal. Researchers will track how many achieve remission or low disease activity over 5 years, as well as side effects and quality of life. The goal is to see if the drug works as well in real-world clinics as it did in earlier trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anifrolumab
What this could lead to: If successful, this study could confirm that anifrolumab helps more lupus patients achieve remission or low disease activity with fewer steroids in everyday practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage real-world evidence, and the drug may not work as well outside clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

University of Pisa
RECRUITING

Pisa, 56100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.